A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)
Latest Information Update: 13 Nov 2023
At a glance
- Drugs Plecanatide (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Acronyms CIC3
- Sponsors Bausch Health Companies; Synergy Pharmaceuticals Inc
- 26 Oct 2022 Results of post hoc pooled analysis from NCT01982240; NCT02122471, NCT02387359, NCT02493452; evaluating the potential impact of age on plecanatide efficacy in Chronic Idiopathic Constipation and IBS-C, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 24 Jan 2022 Results of pooled analysis from (NCT02122471 and NCT01982240) assessing efficacy and safety along with concomitant acid suppression therapy's effect published in the Clinical Therapeutics
- 27 Oct 2021 Results of a post-hoc analysis from two studies (NCT01982240, NCT02122471) presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021